• investorsbanner


Executive Officers

The Horizon Pharma team is comprised of senior executives with extensive experience in biotechnology and pharmaceuticals.

 Mr. Walbert has served as chairman of our board of directors and our president and chief executive officer since our inception in March 2010. Mr. Walbert has also served as the president and chief executive officer of Horizon Pharma USA since June 2008 and on its board of directors since July 2008. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., or IDM, a biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. From January 2006 to May 2007, Mr. Walbert served as executive vice president, commercial operations of NeoPharm, Inc., a biopharmaceutical company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager, Immunology, where he led the global development and launch of HUMIRA, which exceeded $9.0 billion in 2012 sales, and divisional vice president, global cardiovascular strategy at Abbott, a broad-based healthcare company, now AbbVie. From April 1998 to June 2001, Mr. Walbert served as director, Celebrex North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company, or G.D. Searle, a pharmaceutical company. From 1991 to 1998,   Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth. Mr. Walbert received his B.A. in business from Muhlenberg College, in Allentown, Pennsylvania. Mr. Walbert also serves on the board of directors of XOMA Ltd. (NASDAQ: XOMA), Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Egalet Corporation (NASDAQ: EGLT), the Biotechnology Industry Organization (BIO), the Illinois Biotechnology Industry Organization (iBIO), ChicagoNEXT, a World Business Chicago (WBC) led council of technology leaders and the Greater Chicago Arthritis Foundation. Our board believes that Mr. Walbert’s business expertise, including his prior executive level leadership, give him the operational expertise, breadth of knowledge and valuable understanding of our industry, which qualify him to serve as a director and to lead our board as chairman.

Mr. De Vaere has served as our executive vice president and chief financial officer since our inception in March 2010 and as the executive vice president and chief financial officer of Horizon Pharma USA since October 2008. From May 2007 to June 2009, Mr. De Vaere served as senior vice president, finance and administration and chief financial officer at IDM, which was acquired by Takeda in 2009. From August 2006 to April 2007, Mr. De Vaere served as chief financial officer at Nexa Orthopedics, Inc., a medical device company, which was acquired by Tornier, Inc. in February 2007. From August 2005 to March 2006, Mr. De Vaere served as vice president, finance and administration and chief financial officer at IDM. From May 2000 to August 2005, Mr. De Vaere served as vice president and chief financial officer at Epimmune Incorporated, a pharmaceutical company focused on the development of vaccines, which was combined with IDM in August 2005. Prior to 2000, Mr. De Vaere served as vice president of finance and administration and chief financial officer at Vista Medical Technologies, Inc., a medical device company. Mr. De Vaere received his B.S. from the University of California, Los Angeles.

Prior to joining Horizon, Mr. Carey spent more than 11 years as managing director and head of the life sciences investment banking group at JMP Securities LLC, a full-service investment bank. Prior to JMP, Mr. Carey was a managing director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities. Mr. Carey also has held roles at Red Hen Bread, InStadium, Shearson Lehman Hutton and Ernst & Whinney.

Mr. Carey has assisted biotech and specialty pharma companies raise more than $10 billion in initial public offerings, follow-on offerings, debt offerings and private placements. He has also served as a financial advisor on mergers, acquisitions and strategic alliance transactions with a total deal value of more than $3 billion.

Mr. Carey holds a bachelor's degree from the University of Notre Dame.

 Dr. Sherman has served as our executive vice president, development, manufacturing, and regulatory affairs, and chief medical officer since June 2011, as our executive vice president, development and regulatory affairs and chief medical officer since our inception in March 2010 and as the executive vice president, development and regulatory affairs and chief medical officer of Horizon Pharma USA since June 2009.

From June 2009 through June 2010, Dr. Sherman served as president and board member of the Drug Information Association (DIA), a nonprofit professional association of members who work in government regulatory, academia, patient advocacy and the pharmaceutical and medical device industry. Dr. Sherman isa former president of DIA and serves as DIA liaison to the Clinical Trial Transformation Initiative (CTTI) a public-private partnership founded by the US Food and Drug Administration and Duke University to improve the quality and efficiency of clinical trials. He also serves on the Board of Advisors of the Center for Information and Study on Clinical Research Participation (CISCRP) a nonprofit organization dedicated to educating and informing the public, patients, medical/research communities, the media and policy makers about clinical research and the role each party plays in the process. He is an adjunct assistant professor of medicine at the Northwestern University Feinberg School of Medicine and is a member of a number of professional societies, as well as a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine.

From August 2007 through June 2009, Dr. Sherman served as senior vice president of research and development and chief medical officer at IDM Pharma, which was acquired by Takeda in 2009. From June 2007 through August 2007, he served as vice president of clinical science at Takeda Global Research and Development. From September 2000 through June 2007, Dr. Sherman served as chief medical officer and executive vice president at NeoPharm, Inc., a biopharmaceutical company.

From October 1992 through August 2000, Dr. Sherman served as director, senior director and executive director of clinical research, and was head of oncology global medical operations at Searle/Pharmacia, or Searle, a pharmaceutical company. Prior to joining Searle, Dr. Sherman worked in clinical pharmacology and clinical research at Bristol-Myers Squibb Company, a biopharmaceutical company. Dr. Sherman received his medical degree from the Rosalind Franklin University/Chicago Medical School. He completed an internal medicine internship, residency and chief medical residency at Northwestern University, as well as fellowship training at the University of California, San Francisco (UCSF). Dr. Sherman was also a research associate at the Howard Hughes Medical Institute at UCSF.

Mr. Smith has served as our executive vice president and chief commercial officer since February 2012. Prior to that, Mr. Smith served as our senior vice president, sales, marketing and business development of Horizon Pharma USA since October 1, 2010. Before joining Horizon Pharma, Mr. Smith served as vice president, global marketing, strategy and business development at Fenwal Inc., a global medical device company formed through a TPG financed spin-off from Baxter. Mr. Smith was responsible for Fenwal's global product portfolio, the company's strategic planning and business development initiatives. During this time, Fenwal launched more than 10 products and reignited growth in its core automation businesses.

Mr. Smith has nearly 18 years of pharmaceutical and biotechnology industry experience, holding a succession of senior management roles in sales, marketing and business development at top 20 pharma companies, including Abbott and Bayer, as well as venture-backed biotechs, including Agouron and Achillion.

As a sales and marketing executive, Mr. Smith has either led or been part of more than 12 product launches. He led both sales and marketing activities for the Virology Franchise at Abbott, including the launch of Kaletra tablets (a critical life-cycle reformulation), where global sales grew to more than $1 billion. In his business development roles, he has structured licensing deals and joint ventures and managed alliances regionally and globally.

He earned a bachelor's degree in political science from Norwich University

Mr. Hoelscher joins Horizon from OfficeMax, Inc. where he was most recently Senior Vice President, Finance and was co-lead in integration planning activities related to its recent merger with Office Depot. Prior to that, Mr. Hoelscher spent almost nineteen years at Alberto Culver/Unilever in various senior financial roles progressing to Vice President, Finance. Mr. Hoelscher also spent seven years in public accounting with KPMG LLP and is a Certified Public Accountant. During his time at Alberto Culver/Unilever and OfficeMax, Mr. Hoelscher had broad responsibility for corporate accounting and reporting functions, financial planning and analysis, treasury, corporate development and investor relations, including significant international operations and mergers and acquisitions.

Senior Management

Mr. Beeler is an attorney with more than 15 years’ experience providing legal and business advice and counsel to businesses in the healthcare and life sciences industries.  Brian comes to Horizon from Fenwal, Inc., a global life sciences manufacturer of products for transfusion medicine, where he served as Associate General Counsel.  Prior to Fenwal, he was Senior Counsel, Business Development, Commercial, and Research and Development at TAP Pharmaceutical Products and Takeda Pharmaceuticals North America and also previously served as Chief Compliance Officer at Schwarz Pharma.

Brian is licensed to practice law in the states of Illinois and Indiana.  He received his JD from Indiana University School of Law, his MBA from Kellogg School of Management at Northwestern University, and his BA from Purdue University. 

Mr. Bove joined Horizon Pharma in July 2011.  Prior to joining Horizon Pharma, Ben was with Galt & Company, a specialized consulting firm focused on working with Fortune 500 companies to deliver and sustain superior performance in both the customer and capital markets via improved corporate and business unit strategies, resource allocation and operational efficiency, and organizational capabilities and incentives. Galt & Company has been associated with some of the more notable corporate success stories of the last two decades.

Within healthcare, Ben has had experiences ranging from optimizing commercial activities (both professional and consumer) to reconfiguring global supply chains.  He has also worked across a multitude of other industries including medical device, industrial, automotive, and CPG.

Ben has an MBA from the Kellogg School of Management as well as a bachelor’s degree in Mechanical Engineering and a master’s degree in Engineering Management from Northwestern University.

Amy Grahn is senior vice president, clinical development and operations at Horizon Pharma. Ms. Grahn has more than 20 years of pharmaceutical industry experience spanning pre-clinical research to commercial roles, with a primary focus on clinical operations. She was most recently vice president of clinical operations at MedGenesis Therapeutix Inc. in British Columbia, Canada, where she was responsible for strategic planning, development and implementation of clinical and pre-clinical development plans for therapeutic agents delivered via the MedGenesis convection-enhanced delivery (CED) platform.

Ms. Grahn served as vice president of clinical operations at NeoPharm where she was responsible for the Company's lead compound, IL13-PE38 (under a CRADA with FDA) for recurrent glioblastoma mulitforme, from Phase 1 to completion of Phase 3 in five years. In addition, Ms. Grahn oversaw the progression of two additional compounds from Phase 1 to Phase 2.

During her career, Ms. Grahn has also held various senior level positions at Takeda Pharmaceuticals North America, Inc., Searle and Abbott. She has a master's degree in biochemistry from Illinois Institute of Technology in Chicago and a bachelor's degree in chemistry and biology from Knox College in Galesburg, IL.

Jeffrey D. Kent, M.D., FACG, joined Horizon Pharma in May 2012 as senior vice president, medical affairs. Most recently, Dr. Kent was executive director, medical affairs at Astellas Pharmaceuticals. Prior to Astellas, he spent over 8 years at Abbott as global project head, immunology medical affairs, where he created and led the immunology global medical affairs organization and played a key role in the successful launch and growth of HUMIRA®, Abbott's multi-indication blockbuster biologic for rheumatoid arthritis and other autoimmune disorders, which exceeded $8 billion in 2011 sales. In this role, Dr. Kent's responsibilities included building and organizing the medical affairs organization to focus globally on scientific communications and training, post-approval clinical trials, business development assessments, and external relations. Dr. Kent also worked at Searle Pharmaceuticals from 1999 to 2003, where he participated in the development of several blockbuster COX-2 inhibitors including CELEBREX® and BEXTRA®. While at Searle, Dr. Kent was a key contributor to multiple clinical trials, regulatory submissions, and publications and was promoted to the position of Clinical Program Director, leading the global development program of BEXTRA.

Dr. Kent completed medical school at Jefferson Medical College and completed his residency training in internal medicine at the Thomas Jefferson University Hospital in Philadelphia. Subsequently, Dr. Kent trained in gastroenterology and hepatology at Rush Presbyterian-St. Luke's Medical Center in Chicago. After completing his fellowship, he joined the faculty in the Department of Medicine, Section of Digestive Diseases at RUSH. Dr. Kent subsequently served as Associate Director of the Evanston Hospital Clinical Pharmacology Unit where he obtained experience with Phase I clinical trials with specific emphasis on ADME and first-in-human clinical trials.

Mr. Metz is senior vice president, business operations, human resources and government affairs for Horizon Pharma, Inc. He is responsible for the administration of global business operations including information technology, human resources, facilities, project management and government affairs.  Mr. Metz joined Horizon Pharma in 2009 and brings over 20 years of commercial, finance and administration experience in both small and large pharmaceutical and biotechnology organizations.  Prior to joining Horizon Pharma, Mr. Metz's most recent position was vice president, commercial operations for IDM Pharma, where he played a key role in the turnaround and eventual sale of IDM Pharma to Takeda Pharmaceuticals in June 2009.  He led all sales and marketing efforts, including development of key opinion leader and institution center outreach and pricing and reimbursement programs throughout the European markets.  Prior to joining IDM Pharma, Mr. Metz led commercial operations for NeoPharm, a public oncology biotechnology company.  For nearly 13 years, Mr. Metz worked in areas of increasing responsibility at Searle prior to and following its merger with Pharmacia in 2003 on several products, including Celebrex®, Arthrotec®. Daypro® and Detrol® LA.  His experience encompassed sales, business analysis, business development, commercial operations, human resources project management and government affairs.  In his sales management roles, Mr. Metz directed multifunctional, operational and performance aspects of the company’s Midwest sales organization spanning over 650 sales and support employees with overall sales totaling over $2 billion.  Mr. Metz has also held sales and marketing positions at Medpointe Pharma and Reliable Biopharmaceuticals.  Mr. Metz has a bachelor’s degree in management/economics with a minor in political science from Marietta College in Marietta, OH.


Mr. Whalen joined Horizon in April of 2010 and was named to his current position as senior vice president of business development and alliance management in March of 2013.  Mr. Whalen has more than 19 years of experience in the healthcare industry leading and supporting transactions involving acquisitions, co-promotions, out licenses and strategic alliances.  He led the out licenses of both LODOTRA and DUEXIS ex-U.S., supported Horizon’s IPO and other fund raising activities, and was involved in Horizon’s merger with Nitec (as a consultant). 

Prior to Horizon, he was at Baxter Healthcare where he led and supported a number of transactions as part of Baxter’s Medication Delivery business including a global collaboration with Halozyme for Hylenex®  and  a license and supply agreement with Wyeth for Zosyn®.  Mr. Whalen worked at Searle prior to Baxter where he played a key role in the negotiation of the Celebrex®  co-promotion agreement with Pfizer.  His experience there encompassed various finance roles supporting business development, European operations, U.S. marketing, and R&D. 

 He earned a MBA from the University of Illinois and bachelor’s degree in business administration from the University of Notre Dame.

Hans-Peter Zobel joined Horizon Pharma on June 1st, 2009 and leads manufacturing and supply chain activities in Europe. He also has responsibility for European drug product quality assurance and serves as the General Manager Europe. Prior to joining Horizon Pharma, Dr. Zobel held various management positions at Novartis Pharma AG and Merck KGaA being responsible for the development and production of sterile, topical and solid oral dosage forms.

Dr. Zobel studied pharmacy at the Johannes Gutenberg University in Mainz, Germany, followed by a Ph.D. in pharmaceutical technology at the Johann Wolfgang Goethe University in Frankfurt, Germany.

Powered by WordPress. Designed by Woo Themes